{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:50Z","timestamp":1792608470750,"version":"4.5.0"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.blre.2024.101240","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T06:32:35Z","timestamp":1725431555000},"page":"101240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH"],"prefix":"10.1016","volume":"68","author":[{"given":"Jean","family":"Escal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Poenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Bezzeghoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.blre.2024.101240_bb0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.blre.2024.101240_bb0020","article-title":"Evidence and unresolved questions in pulmonary hypertension: insights from the 5th French pulmonary hypertension network meeting","volume":"86","author":"Boucly","year":"2024","journal-title":"Respir Med Res"},{"key":"10.1016\/j.blre.2024.101240_bb0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01294-2024","article-title":"Chronic thromboembolic pulmonary disease","author":"Kim","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.blre.2024.101240_bb0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","author":"Chin","year":"2024","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000343108","article-title":"The discovery of vitamin K and its clinical applications","volume":"61","author":"Ferland","year":"2012","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.blre.2024.101240_bb0040","doi-asserted-by":"crossref","unstructured":"8: Lee MT, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet 2013 58(6):334\u20138.","DOI":"10.1038\/jhg.2013.40"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/2045893217721903","article-title":"Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers","volume":"7","author":"Roldan","year":"2017","journal-title":"Pulm Circ"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0050","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","article-title":"Direct Oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents","volume":"27","author":"Rose","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.blre.2024.101240_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.phrs.2016.06.023","article-title":"Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism","volume":"118","author":"Bertoletti","year":"2017","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0060","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4103\/jfmpc.jfmpc_2253_21","article-title":"Direct oral anticoagulant: review article","volume":"11","author":"Nasiri","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.blre.2024.101240_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.987652","article-title":"Effects of oral anticoagulant therapy in patients with pulmonary diseases","volume":"9","author":"Lai","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000445122","article-title":"Risk of direct oral anticoagulant bioaccumulation in patients with pulmonary hypertension","volume":"91","author":"Gabriel","year":"2016","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12020","article-title":"Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the global burden of disease 2020 study","volume":"12","author":"Emmons-Bell","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1016\/j.blre.2024.101240_bb0080","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101240_bb0085","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/diseases6020038","article-title":"Pulmonary arterial hypertension: pathophysiology and treatment","volume":"6","author":"Lan","year":"2018","journal-title":"Diseases"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults","volume":"155","author":"Klinger","year":"2019","journal-title":"CHEST"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0100","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","article-title":"Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017)","volume":"83","author":"Fukuda","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.blre.2024.101240_bb0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/01.CIR.42.6.1163","article-title":"Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases","volume":"42","author":"Wagenvoort","year":"1970","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2024.101240_bb0110","first-page":"97","article-title":"Vasoconstrictive primary pulmonary hypertension and pulmonary veno-occlusive disease","volume":"4","author":"Wagenvoort","year":"1972","journal-title":"Cardiovasc Clin"},{"key":"10.1016\/j.blre.2024.101240_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000395210","article-title":"Pathology of the Eisenmenger syndrome and primary pulmonary hypertension","volume":"11","author":"Wagenvoort","year":"1974","journal-title":"Adv Cardiol"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0125","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","article-title":"Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, primary pulmonary hypertension registry","volume":"80","author":"Pietra","year":"1989","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0135","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.98.12061446","article-title":"Plasma coagulation profiles in patients with severe primary pulmonary hypertension","volume":"12","author":"Hoeper","year":"1998","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0272-5231(05)70283-5","article-title":"Pathobiology of pulmonary hypertension. The role of platelets and thrombosis","volume":"22","author":"Herve","year":"2001","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0012-3692(15)51873-4","article-title":"Thrombotic arteriopathy and anticoagulation in pulmonary hypertension","volume":"130","author":"Johnson","year":"2006","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.blre.2024.101240_bb0150","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1164\/rccm.200907-1135OC","article-title":"Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic","volume":"181","author":"Miniati","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0155","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar4051","article-title":"Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study","volume":"14","author":"Ngian","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1378\/chest.14-0862","article-title":"New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication","volume":"147","author":"Guignabert","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.blre.2024.101240_bb0165","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019895451","article-title":"Anticoagulation in pulmonary arterial hypertension: a decision analysis","volume":"9","author":"Jose","year":"2019","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/medicina57020110","article-title":"Review of medical therapies for the management of pulmonary embolism","volume":"57","author":"Panahi","year":"2021","journal-title":"Medicina"},{"issue":"24","key":"10.1016\/j.blre.2024.101240_bb0185","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.blre.2024.101240_bb0190","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1161\/CIRCULATIONAHA.115.019651","article-title":"Whither anticoagulation in pulmonary arterial hypertension? Conflicting evidence REVEALed","volume":"132","author":"Frantz","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0195","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018807681","article-title":"Are anticoagulants still indicated in pulmonary arterial hypertension?","volume":"8","author":"Olschewski","year":"2018","journal-title":"Pulm Circ"},{"issue":"154","key":"10.1016\/j.blre.2024.101240_bb0200","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0050-2019","article-title":"Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations","volume":"28","author":"Swinnen","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"25","key":"10.1016\/j.blre.2024.101240_bb0205","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0210","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101240_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004757","article-title":"Is anticoagulation beneficial in pulmonary arterial hypertension?","volume":"11","author":"Khan","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.blre.2024.101240_bb0220","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.thromres.2020.08.024","article-title":"Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis","volume":"196","author":"Wang","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2024.101240_bb0225","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2024.101240_bb0230","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0235","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00039212","article-title":"Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension","volume":"41","author":"Henkens","year":"2013","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0240","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/pharmaceutics15061579","article-title":"Medical Management of Pulmonary Arterial Hypertension: current approaches and investigational drugs","volume":"15","author":"Jin","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0245","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1183\/09031936.00180512","article-title":"Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!","volume":"41","author":"Bertoletti","year":"2013","journal-title":"Eur Respir J"},{"issue":"67","key":"10.1016\/j.blre.2024.101240_bb0250","article-title":"Bleeding under anticoagulant therapy in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: preliminary results from the HEMA-HTP study","volume":"62","author":"Bezzeghoud","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.blre.2024.101240_bb0260","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.blre.2024.101240_bb0265","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"16","key":"10.1016\/j.blre.2024.101240_bb0270","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2024.101240_bb0275","first-page":"595","article-title":"Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension","volume":"111","author":"Jansa","year":"2010","journal-title":"Bratisl Lek Listy"},{"issue":"17","key":"10.1016\/j.blre.2024.101240_bb0280","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 Expert consensus document on pulmonary hypertension","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101240_bb0285","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2024.101240_bb0290","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002895","article-title":"Interaction between dietary vitamin K intake and anticoagulation by vitamin K antagonists: is it really true?: a systematic review","volume":"95","author":"Violi","year":"2016","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0295","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0300","first-page":"40","article-title":"Alcohol and medication interactions","volume":"23","author":"Weathermon","year":"1999","journal-title":"Alcohol Res Health"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0305","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/1060028013517541","article-title":"Warfarin dosing and body mass index","volume":"48","author":"Mueller","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0310","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.thromres.2015.06.007","article-title":"Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink","volume":"136","author":"Macedo","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0315","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/fcp.12992","article-title":"Latest advances in the reversal strategies for direct oral anticoagulants","volume":"38","author":"Escal","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.blre.2024.101240_bb0320","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv Ther"},{"issue":"9921","key":"10.1016\/j.blre.2024.101240_bb0330","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2024.101240_bb0335","author":"Garza"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0340","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/690018","article-title":"Kidney dysfunction in patients with pulmonary arterial hypertension","volume":"7","author":"Nickel","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.blre.2024.101240_bb0345","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2024.101240_bb0350","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2024.101240_bb0355","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2024.101240_bb0360","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/clc.23085","article-title":"Atrial fibrillation and chronic kidney disease: a review of options for therapeutic anticoagulation to reduce thromboembolism risk","volume":"41","author":"Bhatia","year":"2018","journal-title":"Clin Cardiol"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0365","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin Cardiol"},{"issue":"17","key":"10.1016\/j.blre.2024.101240_bb0370","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.blre.2024.101240_bb0375","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct Oral anticoagulants versus warfarin across the Spectrum of kidney function: patient-level network Meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0380","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin Cardiol"},{"issue":"23","key":"10.1016\/j.blre.2024.101240_bb0385","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0390","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3390\/ijerph19031436","article-title":"Safety and efficacy of DOACs in patients with advanced and end-stage renal disease","volume":"19","author":"Rogula","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0395","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211054304","article-title":"Liver abnormalities in pulmonary arterial hypertension","volume":"11","author":"Nickel","year":"2021","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0400","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/medicina59020346","article-title":"Oral anticoagulation in patients with chronic liver disease","volume":"59","author":"Costache","year":"2023","journal-title":"Medicina"},{"issue":"10","key":"10.1016\/j.blre.2024.101240_bb0405","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.blre.2024.101240_bb0410","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/CIRCOUTCOMES.113.000817","article-title":"Stratifying the risks of oral anticoagulation in patients with liver disease","volume":"7","author":"Efird","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"19","key":"10.1016\/j.blre.2024.101240_bb0415","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.blre.2024.101240_bb0420","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","article-title":"Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101240_bb0425","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00228-011-1086-4","article-title":"Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources","volume":"67","author":"Martins","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100137","article-title":"Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review","volume":"7","author":"Candeloro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"15","key":"10.1016\/j.blre.2024.101240_bb0435","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0440","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2125.2006.02613.x","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein","volume":"61","author":"Shimizu","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.blre.2024.101240_bb0445","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025723","article-title":"Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation","volume":"11","author":"Xu","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0450","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0455","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/pharmaceutics11030133","article-title":"Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of rivaroxaban","volume":"11","author":"Kim","year":"2019","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0460","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3593","article-title":"Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function","volume":"3","author":"Pham","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.blre.2024.101240_bb0465","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2024.3867","article-title":"Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban","volume":"331","author":"Ray","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0470","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"49","author":"Hanigan","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2024.101240_bb0475","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug\u2013Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0480","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjcard.2017.05.026","article-title":"Efficacy and safety of rivaroxaban versus warfarin in patients taking Nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF trial)","volume":"120","author":"Washam","year":"2017","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.blre.2024.101240_bb0485","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K Oral anticoagulants with and without concurrent medications and risk of major bleeding in Nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0490","article-title":"Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation","volume":"35","author":"Sychev","year":"2020","journal-title":"Drug Metab Pers Ther"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0495","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/17151635221116100","article-title":"DOAC drug interactions management resource","volume":"155","author":"Chadha","year":"2022","journal-title":"Can Pharm J"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0500","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1248\/bpb.b20-00791","article-title":"Comprehensive exploration of medications that affect the bleeding risk of oral anticoagulant users","volume":"44","author":"Kawano","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"10.1016\/j.blre.2024.101240_bb0505","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0510","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","article-title":"Drug and dietary interactions of warfarin and novel oral anticoagulants: an update","volume":"31","author":"Nutescu","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.blre.2024.101240_bb0520","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-011-1031-6","article-title":"Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database","volume":"67","author":"Jobski","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101240_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.933215","article-title":"Edema formation in congestive heart failure and the underlying mechanisms","volume":"9","author":"Abassi","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.blre.2024.101240_bb0530","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1111\/bcp.14833","article-title":"Drug-drug interactions with warfarin: a systematic review and meta-analysis","volume":"87","author":"Wang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"2\u20133","key":"10.1016\/j.blre.2024.101240_bb0535","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/j.1552-4604.1978.tb02426.x","article-title":"The effect of furosemide and bumetanide on warfarin metabolism and anticoagulant response","volume":"18","author":"Nilsson","year":"1978","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0540","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/14740338.2012.624091","article-title":"Effect of oral diuretics on chronic warfarin therapy: a retrospective study","volume":"11","author":"Edwards","year":"2012","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0545","first-page":"54","article-title":"Effect of diuretics on the pharmacologic action of warfarin","volume":"7","author":"Bloukh","year":"2018","journal-title":"Sch Acad J Pharm"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0550","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.1980.31","article-title":"Spironolactone and warfarin interaction","volume":"27","author":"O\u2019Reilly","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0555","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt.1845","article-title":"Pharmacoepidemiologic screening of potential oral anticoagulant drug interactions leading to thromboembolic events","volume":"108","author":"Zhou","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0560","doi-asserted-by":"crossref","first-page":"70","DOI":"10.18203\/2319-2003.ijbcp20205541","article-title":"Drug interactions of oral anticoagulants","volume":"10","author":"Anil","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"Suppl. 14","key":"10.1016\/j.blre.2024.101240_bb0565","doi-asserted-by":"crossref","first-page":"S1767","DOI":"10.21037\/jtd.2019.09.14","article-title":"Pharmacotherapy for pulmonary arterial hypertension","volume":"11","author":"Parikh","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.blre.2024.101240_bb0570","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1741-7015-2-8","article-title":"Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring","volume":"2","author":"Englund","year":"2004","journal-title":"BMC Med"},{"issue":"14","key":"10.1016\/j.blre.2024.101240_bb0575","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0580","doi-asserted-by":"crossref","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0585","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","article-title":"Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects","volume":"52","author":"Atsmon","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"8567","key":"10.1016\/j.blre.2024.101240_bb0590","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(87)91481-4","article-title":"Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium","volume":"330","author":"Radomski","year":"1987","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2014.01.004","article-title":"The impact of drug-drug interactions on pulmonary arterial hypertension therapy","volume":"28","author":"Cirac\u00ec","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0600","first-page":"391","article-title":"Prostacyclin therapy for pulmonary arterial hypertension","volume":"37","author":"Ruan","year":"2010","journal-title":"Tex Heart Inst J"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0605","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.blre.2024.101240_bb0610","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0615","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.blre.2024.101240_bb0620","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.blre.2024.101240_bb0625","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0630","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0635","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.chest.2022.06.042","article-title":"Drug-drug interactions in the management of patients with pulmonary arterial hypertension","volume":"162","author":"Wu","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0640","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0645","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"Patent plus: a blinded, randomised and extension study of riociguat plus sildenafil in PAH","volume":"45","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0650","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101240_bb0655","author":"EMA"},{"issue":"7\u20138","key":"10.1016\/j.blre.2024.101240_bb0660","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1345\/aph.1C398","article-title":"Bosentan and warfarin interaction","volume":"37","author":"Murphey","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0665","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2010.01.004","article-title":"Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli","volume":"32","author":"Spangler","year":"2010","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0670","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.121.007956","article-title":"Drug interactions affecting Oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"18","key":"10.1016\/j.blre.2024.101240_bb0675","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/jcm12185955","article-title":"Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios","volume":"12","author":"Luc\u00e0","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101240_bb0680","author":"EMA"},{"key":"10.1016\/j.blre.2024.101240_bb0685","author":"EMA"},{"key":"10.1016\/j.blre.2024.101240_bb0690","author":"EMA"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0695","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40261-014-0207-0","article-title":"Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects","volume":"34","author":"Sidharta","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0700","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2009.03384.x","article-title":"The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers","volume":"67","author":"Walker","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.blre.2024.101240_bb0705","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1111\/bcp.13757","article-title":"Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John\u2019s wort should be avoided","volume":"84","author":"Huppertz","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101240_bb0710","author":"EMA"},{"key":"10.1016\/j.blre.2024.101240_bb0715","author":"EMA"},{"key":"10.1016\/j.blre.2024.101240_bb0720","author":"EMA"},{"issue":"7","key":"10.1016\/j.blre.2024.101240_bb0725","doi-asserted-by":"crossref","DOI":"10.1177\/0091270010378119","article-title":"Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study","volume":"51","author":"Frey","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101240_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106241","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.blre.2024.101240_bb0735","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/fcp.12504","article-title":"In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants","volume":"34","author":"Jacqueroux","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0740","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.117.245993","article-title":"In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: type 5-phosphodiesterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by P-glycoprotein","volume":"365","author":"Margelidon-Cozzolino","year":"2018","journal-title":"J Pharmacol Exp Ther Juin"},{"issue":"10","key":"10.1016\/j.blre.2024.101240_bb0745","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11095-020-02927-4","article-title":"Intestinal efflux transporters P-gp and BCRP are not clinically relevant in Apixaban disposition","volume":"37","author":"Sodhi","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.blre.2024.101240_bb0750","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct Oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0755","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/688059","article-title":"An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension","volume":"6","author":"Zamanian","year":"2016","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0760","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/ers.12.23","article-title":"Inhaled treprostinil for the treatment of pulmonary arterial hypertension","volume":"6","author":"LeVarge","year":"2012","journal-title":"Expert Rev Respir Med"},{"issue":"13","key":"10.1016\/j.blre.2024.101240_bb0765","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.blre.2024.101240_bb0770","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of Sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101240_bb0775","author":"FDA"},{"issue":"10","key":"10.1016\/j.blre.2024.101240_bb0780","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.blre.2024.101240_bb0785","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9","article-title":"Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Frantz","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"143","key":"10.1016\/j.blre.2024.101240_bb0790","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2016","article-title":"The pathophysiology of chronic thromboembolic pulmonary hypertension","volume":"26","author":"Simonneau","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0795","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020977300","article-title":"Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review","volume":"11","author":"Leber","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.blre.2024.101240_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106293","article-title":"Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension","volume":"177","author":"Ghofrani","year":"2021","journal-title":"Respir Med"},{"issue":"21","key":"10.1016\/j.blre.2024.101240_bb0805","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.jacc.2018.04.009","article-title":"Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease","volume":"71","author":"Mahmud","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2024.101240_bb0810","article-title":"How I do it: a collaborative, interinstitutional program to improve the care of patients with chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"100092","author":"Kelly","year":"2024","journal-title":"CHEST Pulm"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0815","doi-asserted-by":"crossref","first-page":"157","DOI":"10.32604\/chd.2024.047930","article-title":"Treatment and clinical Management of Chronic Thromboembolic Pulmonary Hypertension: an update of literature review","volume":"19","author":"Ren","year":"2024","journal-title":"Congenit Heart Dis"},{"issue":"143","key":"10.1016\/j.blre.2024.101240_bb0820","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2016","article-title":"The pathophysiology of chronic thromboembolic pulmonary hypertension","volume":"26","author":"Simonneau","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"18","key":"10.1016\/j.blre.2024.101240_bb0825","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","article-title":"Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry","volume":"124","author":"Pepke-Zaba","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.blre.2024.101240_bb0830","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1183\/09031936.00087608","article-title":"Risk factors for chronic thromboembolic pulmonary hypertension","volume":"33","author":"Bonderman","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.blre.2024.101240_bb0835","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1378\/chest.103.3.685","article-title":"Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension","volume":"103","author":"Moser","year":"1993","journal-title":"Chest"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2024.101240_bb0840","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1513\/AnnalsATS.201509-620AS","article-title":"The pathobiology of chronic thromboembolic pulmonary hypertension","volume":"13","author":"Lang","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.blre.2024.101240_bb0845","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/j.jacc.2004.02.033","article-title":"Pathologic assessment of vasculopathies in pulmonary hypertension","volume":"43","author":"Pietra","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2024.101240_bb0850","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1164\/rccm.200702-278OC","article-title":"Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension","volume":"176","author":"Skoro-Sajer","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2024.101240_bb0855","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-642-38664-0_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Handb Exp Pharmacol"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0860","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1253\/circj.70.1058","article-title":"Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension","volume":"70","author":"Reesink","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.blre.2024.101240_bb0865","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lfs.2016.02.036","article-title":"Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension","volume":"159","author":"Southwood","year":"2016","journal-title":"Life Sci"},{"issue":"7","key":"10.1016\/j.blre.2024.101240_bb0870","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00392-018-1215-5","article-title":"Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany","volume":"107","author":"Kramm","year":"2018","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0875","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019873545","article-title":"Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study","volume":"10","author":"Sena","year":"2020","journal-title":"Pulm Circ"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101232","article-title":"Head-to-head comparison between direct Oral anticoagulants and vitamin K antagonists for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis","volume":"48","author":"Burmeister","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0885","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11239-021-02501-8","article-title":"Use of direct oral anticoagulants in chronic thromboembolic pulmonary hypertension: a systematic review","volume":"53","author":"Sedhom","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.blre.2024.101240_bb0890","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","article-title":"Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension","volume":"41","author":"Humbert","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.blre.2024.101240_bb0895","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/jth.14649","article-title":"A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension","volume":"18","author":"Bunclark","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.blre.2024.101240_bb0900","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28033","article-title":"Clinical outcomes of direct Oral anticoagulants vs warfarin for extended treatment of venous thromboembolism","volume":"6","author":"Fang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.blre.2024.101240_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102377","article-title":"Clinical outcomes between direct oral anticoagulants versus vitamin K antagonists in chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis","volume":"49","author":"Salazar","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"10.1016\/j.blre.2024.101240_bb0910","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/CIRCULATIONAHA.123.067528","article-title":"A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial","volume":"149","author":"Hosokawa","year":"2024","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.blre.2024.101240_bb0915","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101240_bb0920","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2024.101240_bb0925","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101240_bb0930","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.blre.2024.101240_bb0935","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.blre.2024.101240_bb0940","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1253\/circrep.CR-21-0034","article-title":"Results of Macitentan in Japanese patients with chronic thromboembolic pulmonary hypertension - a prospective, multicenter, open-label, single-arm, phase 3 study","volume":"3","author":"Sakurai","year":"2021","journal-title":"Circ Rep"},{"key":"10.1016\/j.blre.2024.101240_bb0945","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1253\/circj.CJ-20-0438","article-title":"Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients: a double-blind, randomized, placebo-controlled, multicenter phase II study","volume":"84","author":"Tanabe","year":"2020","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.blre.2024.101240_bb0950","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01694-2021","article-title":"Selexipag for the treatment of chronic thromboembolic pulmonary hypertension","volume":"60","author":"Ogo","year":"2022","journal-title":"Eur Respir J"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:58:25Z","timestamp":1731585505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":190,"alternative-id":["S0268960X24000730"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101240","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101240"}}